Urticaria

57

Pipeline Programs↗

6

Active Trials↗

33

Companies Involved↗

Urticaria is a moderately active landscape with 57 programs across 33 companies. The most active players are Granular Therapeutics Limited, Escient Pharmaceuticals, Inc, Bristol-Myers Squibb. 15 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

11/100

Mech. Concentration

24/100

Completion Rate

79/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Granular Therapeutics Limited

1 program

Escient Pharmaceuticals, Inc

1 program

Bristol-Myers Squibb

1 program

Jasper Therapeutics, Inc.

1 program

Clinuvel Pharmaceuticals Limited

1 program

ARS Pharmaceuticals, Inc.

1 program

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

47 of 60 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 60 classified programs, each share of the total. Modality classified for 100% of 62 pipeline programs.

Analysis

Trial Status

56

clinical trials

Completed34 · 61%

Unknown status7 · 13%

Terminated6 · 11%

Recruiting3 · 5%

Withdrawn3 · 5%

Not yet recruiting2 · 4%

Other1 · 2%

Clinical Trials

Trial Activity

56 trials

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Recruiting· Novartis logo

Novartis·Phase 2·NCT06865651·44 enrolled

Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria

Recruiting·SShandong New Time Pharmaceutical Co., LTD·Phase 3·NCT06819774·284 enrolled

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

Recruiting·GGranular Therapeutics Limited·Phase 1·NCT07181369·72 enrolled

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Active, not recruiting·JJasper Therapeutics, Inc.·Phase 2·NCT06736262·67 enrolled

Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria

Not yet recruiting·UUniversity of Phayao·N/A·NCT07236372·140 enrolled

Treatment Options for Chronic Urticaria

Not yet recruiting·SSheikh Zayed Medical College·Phase 2·NCT06816784·72 enrolled

Cholinergic Urticaria - Efficacy of Dupilumab

Completed·—·Phase 2·NCT03749148·48 enrolled

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

Completed·JJDP Therapeutics, Inc.·Phase 3·NCT02023164·36 enrolled

An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)

Completed·—·Phase 3·NCT01916967·239 enrolled

Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency

Completed·UUniversity Hospital, Toulouse·Phase 2/3·NCT02565680·100 enrolled

Phase II Solar Urticaria (SU) Pilot Study

Completed·CClinuvel Pharmaceuticals Limited·Phase 2·NCT00859534·5 enrolled

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

Completed·AARS Pharmaceuticals, Inc.·Phase 2·NCT05496465·24 enrolled

Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria

Completed·—·Phase 2·NCT01713725·20 enrolled

Effect of Anti-IgE in Chronic Urticaria

Completed·JJohns Hopkins University·Phase 2·NCT00130234·20 enrolled

CUTE (Chronic Urticaria Treatment Evaluation)

Completed· UCB logo

UCB·Phase 4·NCT00264303·886 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)